Drug Development Drug Pricing Drug Manufacturers Market Trends Drug Manufacturing Market Analysis Market Competition Manufacturing Pricing Strategies Regulatory Affairs Active Pharmaceutical Ingredients Direct-to-Consumer Sales Government Contracts Product Launches Public Contracts Biotechnology Supply Chain Management Weight Loss Medications Rare Diseases Market Dynamics Pharmaceutical Companies Clinical Trials Vaccine Manufacturers Regulations Drug Pricing Strategies Kusum Healthcare International Business Specialty Medicines Discount Programs Precision Medicine Medicine Distribution Clinical Research Online Platforms Revenue Growth Company Performance Generic Drugs Investment Rebate Programs Drug Innovation Pricing Market Access Drug Procurement Marketing Marketing Strategies Trade Agreements CVS Health Direct Sales Market Challenges Generic Medications Specialty Pharmaceuticals Drug Demand Drug Approval Process Weight-loss Drugs Consumer Services Workplace Culture Data Resources Drug Approval Drug Sales Formulations Product Development Healthcare Ventures Clinical Research Organizations Drug Regulation AI Partnerships Cannabis Production Cancer Treatments Commercial Operations Domestic Market Weight-Loss Drugs Market Targeted Therapies Contract Research Organizations Contract Manufacturing Weight Loss Treatment Diabetes Medications Market Agreements Retail Pharmacy Corporate Operations Regulatory Changes Profitability Challenges Drug Reimbursement Prescription Drugs Corruption Investigations Company News Export Growth Obesity Treatments Diabetes Treatment Prescription Drug Pricing Drug Companies Drug Prices Acquisitions Corporate Leadership Pharmacy Benefit Managers Company Operations
The company set an FDA end-of-Phase-2 meeting for Q2 2026 ahead of a planned Phase 3 start in the second half of the year.
